Pharmaceutical Preparations · DE · CIK 1579428
Develops novel therapies for central nervous system disorders with limited treatment options
Comparable business profile · signals at a glance
In the 90 days to Feb 26, 2026: 6 sold $61.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 26, 2026 | Jacobson Mark L.Chief Operating Officer | Sell | 35,378 | $161.88 | $5.7M |
| Feb 26, 2026 | Coleman MarkDirector | Sell | 25,000 | $161.11 | $4.0M |
| Feb 2, 2026 | Tabuteau HerriotChief Executive Officer | Sell | 32,410 | $185.60 | $6.0M |
| Jan 22, 2026 | Pizzie NickChief Financial Officer | Sell | 12,000 | $187.92 | $2.3M |
| Jan 21, 2026 | Maizel AriChief Commercial Officer | Sell | 7,500 | $184.44 | $1.4M |
| Jan 7, 2026 | Tabuteau HerriotChief Executive Officer | Sell | 31,261 | $170.38 | $5.3M |
| Jan 6, 2026 | Tabuteau HerriotChief Executive Officer | Sell | 29,450 | $172.33 | $5.1M |
| Jan 5, 2026 | Tabuteau HerriotChief Executive Officer | Sell | 78,703 | $171.28 | $13.5M |
| Dec 31, 2025 | Saad Mark EDirector | Sell | 31,346 | $165.18 | $5.2M |
| Dec 31, 2025 | Saad Mark EDirector | Sell | 6,231 | $165.18 | $1.0M |
| Dec 4, 2025 | Tabuteau HerriotChief Executive Officer | Sell | 10,558 | $148.18 | $1.6M |
| Dec 3, 2025 | Tabuteau HerriotChief Executive Officer | Sell | 20,163 | $146.94 | $3.0M |
| Dec 2, 2025 | Tabuteau HerriotChief Executive Officer | Sell | 49,252 | $144.59 | $7.1M |
| Nov 5, 2025 | Tabuteau HerriotChief Executive Officer | Sell | 21,775 | $134.49 | $2.9M |
| Nov 4, 2025 | Tabuteau HerriotChief Executive Officer | Sell | 50,459 | $133.79 | $6.8M |
| Nov 3, 2025 | Tabuteau HerriotChief Executive Officer | Sell | 91,705 | $132.34 | $12.1M |
| Oct 8, 2025 | Tabuteau HerriotChief Executive Officer | Sell | 12,774 | $118.84 | $1.5M |
| Oct 7, 2025 | Tabuteau HerriotChief Executive Officer | Sell | 13,390 | $118.77 | $1.6M |
| Oct 6, 2025 | Tabuteau HerriotChief Executive Officer | Sell | 19,220 | $120.17 | $2.3M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.